## URINARY KIM-1 AS A BIOMARKER OF AMINOGLYCOSIDE-INDUCED NEPHROTOXICITY IN PREMATURE NEONATES

**S.J. McWilliam**<sup>1</sup>, D.J. Antoine<sup>2</sup>, M. Turner<sup>3</sup>, V. Sabbisetti<sup>4</sup>, J.V. Bonventre<sup>4</sup>, B.K. Park<sup>2</sup>, R.L. Smyth<sup>1</sup>, M. Pirmohamed<sup>2</sup>

<sup>1</sup>University of Liverpool, Alder Hey Children's Hospital, <sup>2</sup>MRC Centre for Drug Safety Science, The University of Liverpool, <sup>3</sup>University of Liverpool, Liverpool Women's Hospital, Liverpool, UK, <sup>4</sup>Bonventre Lab, Brigham and Women's Hospital, Boston, MA, USA

**Background and aims:** Premature neonates are frequently exposed to aminoglycoside (AG) antibiotics, which are potentially nephrotoxic. Novel urinary biomarkers may provide a non-invasive means of identifying early changes of AG-related renal proximal tubule toxicity, to enable adjustment of treatment, and identification of infants at risk of long-term renal impairment.

**Methods:** Urine samples were collected from 41 premature neonates (< 32 weeks gestation) at least once per week, and daily during courses of gentamicin and for 3 days afterwards. We assessed the associations between three urinary biomarkers (Kidney Injury Molecue-1 (KIM-1), Neutrophil Gelatinase-associated Lipocalin (NGAL), and N-acetyl-β-D-glucosaminidase (NAG)) and AG exposure.

**Results:** Treatment with gentamicin was associated with significant increases in KIM-1 (mean difference from not treated, 1.64ng/mg urinary Creatinine (uCr); 95% Confidence Interval (CI); 0.54, 2.75), NGAL (453.6ng/mg uCr; 95%CI 145.1, 762.2), and NAG (0.08 IU/mg uCr; 95%CI 0.02, 0.15). There was a reduction in serum creatinine (-4.64micromol/l; 95% CI -8.64, -0.64) during AG treatment. When adjusted for potential confounders the treatment effect of gentamicin remained significant only for KIM-1 (1.35ng/mg uCr; 95% CI 0.05, 2.65). Between courses of gentamicin each biomarker returned to values observed when not receiving gentamicin. Gestational age had no significant effect upon the elevation in urinary biomarkers associated with AG treatment.

**Conclusions:** These findings suggest that KIM-1 may have clinical utility as a sensitive and specific biomarker of AG-associated nephrotoxicity in premature neonates.